system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, METHODS, METHODS, RESULTS. Meshes: Acneiform Eruptions, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Drug Eruptions, Female, Humans, Lapatinib, Middle Aged, Neoadjuvant Therapy, Prospective Studies, Quinazolines, Receptor, ErbB-2, Treatment Outcome.
user
Does development of acneiform rash predict response to lapatinib treatment in patients with breast cancer? Context: To determine if development of acneiform rash is a predictor of objective response rate with lapatinib. Subanalysis of data from a prospective, phase II study. Academic breast care clinic. Forty-nine treatment-naïve patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced breast cancer, who were treated with neoadjuvant lapatinib monotherapy for 6 weeks; 47 patients were included in the final analysis. Of the 49 patients enrolled, 33 (67%) developed a rash of any type, and 26 (55%) had acneiform rash. Of the 26 evaluable patients with acneiform rash (55%), 19 (73%) responded to lapatinib and 7 (27%) did not. Of the 21 evaluable patients without acneiform rash, 11 (67%) responded to treatment and 7 (33%) did not. Thus, no association was found between the occurrence of acneiform rash and response to lapatinib monotherapy.
assistant
This study does not support the development of the acneiform rash as a predictor of clinical efficacy of lapatinib in the treatment of breast cancer. Final Decision: no